Positive treatment updates announced from Ph 2 clinical trial, THIO-101, of THIO + cemiplimab (Libtayo®) in heavily pre-treated patients with advanced NSCLC July 30, 2024
CHMP recommends RYBREVANT + chemo for the treatment of adult patients with advanced EGFR-mutated NSCLC after failure of prior therapy July 30, 2024
Positive feedback received from FDA on the planned TACTI-004 Ph 3 trial of eftilagimod alfa + KEYTRUDA + chemo for the treatment of 1L NSCLC July 30, 2024
Positive Interim Ph 2 Monotherapy Expansion Data for IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced July 17, 2024
FAILED TRIAL: Ph 2/3 SKYSCRAPER-06 trial of tiragolumab, Tecentriq and chemo did not meet the primary endpoints of PFS at primary analysis and OS at first interim analysis July 9, 2024
RYBREVANT (amivantamab) + chemo approved in the EU for 1L treatment of patients with advanced NSCLC with activating EGFR ex 20 insertion mutations July 9, 2024
Focus on vebreltinib study enrollment for NSCLC patients with Met Amplification mutations announced July 9, 2024
Patritumab Deruxtecan BLA Submission Receives CRL from FDA Due to Inspection Findings at Third-Party Manufacturer July 1, 2024
FAILED TRIAL: ADJUVANT BR.31 Ph 3 trial of Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of DFS vs placebo in early-stage (IB-IIIA) NSCLC July 1, 2024
GALAXIES Lung-301 Ph 3 study of Belrestotug and Dostarlimab in 1L Unresectable Locally Advanced/Metastatic PD-L1 Selected NSCLC initiated June 25, 2024
IND Filing for PFL-002/VERT-002 for Patients with Solid Tumors Including NSCLC with MET Alterations June 11, 2024
FDA grants Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR WT NSCLC June 4, 2024
FAILED TRIAL: Datopotamab deruxtecan showed clinically meaningful OS improvement vs. chemo in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial May 29, 2024
NMPA of China Accepted and Granted Priority Review Designation to the NDA for Glecirasib May 29, 2024
U.S. FDA Accepts and grants Priority Review of BLA for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 15, 2024
Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in interim assessment of Ph 2 GALAXIES Lung-201 May 15, 2024
